Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Account Payables (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Change in Account Payables for 13 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 51.46% year-over-year to -$1.1 million, compared with a TTM value of $1.7 million through Dec 2025, down 73.55%, and an annual FY2025 reading of $1.7 million, down 73.55% over the prior year.
  • Change in Account Payables was -$1.1 million for Q4 2025 at Agios Pharmaceuticals, down from $1.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $8.1 million in Q4 2022 and bottomed at -$9.8 million in Q1 2023.
  • Average Change in Account Payables over 5 years is $245650.0, with a median of $337000.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables soared 550.2% in 2021, then tumbled 297.27% in 2025.
  • Year by year, Change in Account Payables stood at $5.2 million in 2021, then surged by 55.08% to $8.1 million in 2022, then plummeted by 143.8% to -$3.5 million in 2023, then surged by 78.6% to -$756000.0 in 2024, then crashed by 51.46% to -$1.1 million in 2025.
  • Business Quant data shows Change in Account Payables for AGIO at -$1.1 million in Q4 2025, $1.8 million in Q3 2025, and $3.9 million in Q2 2025.